Two recent studies reveal that the efficacy of Bavarian Nordic's Mpox vaccine significantly declines within 6-12 months ...

Amid the rising global outbreak of Mpox, two separate studies have shown that the efficacy of Bavarian Nordic’s vaccine ...

Jynneos, developed in 2019 by Bavarian Nordic, is supposed to be administered as two doses given 28 days apart. A live ...

Responding to rising mpox cases in Africa, the World Health Organization declared a public health emergency of international ...

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.

The Vaccine Alliance, Gavi, and Bavarian Nordic announced an Advance Purchase Agreement on Wednesday to secure 500,000 doses ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Corp. with ...

Social media users claim a vaccine approved for use against mpox could cause a smallpox outbreak, but the only thing ...

In an emulated target trial, a single dose of modified vaccinia Ankara-Bavarian Nordic vaccine was moderately effective in ...

One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) smallpox vaccine is moderately effective in preventing mpox ...

The rate of mpox infection in the vaccinated group was 0.09 for every 1,000 person-days as compared to 0.20 in the ...

One dose of modified vaccinia Ankara-Bavarian Nordic vaccine is moderately effective against mpox infection in at-risk communities.